LivaNova PLC (LIVN) News
Follow LivaNova PLC (LIVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A LivaNova PLC Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:19 PM UTC
M
LivaNova Reports Third-Quarter Revenue of $393.15 Million
LivaNova reported third-quarter 2026 revenue of $393.15 million, up 9.9% year over year. Net income rose 28% to $34.29 million, while diluted EPS was $0.11 versus $0.49 a year earlier.
EQUITY | Nov 04, 2026, 08:11 PM UTC
M
LivaNova Reports Q3 Revenue of $393.1 Million, Raises 2026 Guidance
LivaNova reported Q3 revenue of $393.1 million, up 9.9% year over year on a reported basis and 10.0% on a constant-currency basis, with adjusted diluted EPS of $1.23. It raised 2026 revenue-growth guidance to 9%–10% and
EQUITY | Nov 04, 2026, 02:03 PM UTC
M
LivaNova Raises Full-Year Earnings and Revenue-Growth Projections
The medical-technology maker lifted its adjusted earnings and revenue-growth projections for the year. Its shares rose 12% to $89.94 premarket Wednesday.
EQUITY | Nov 04, 2026, 01:28 PM UTC
M
LivaNova Raises 2026 Revenue Growth Forecast to 9%-10%
LivaNova raised its 2026 constant-currency revenue growth forecast to 9%-10%.
EARNINGS | Nov 04, 2026, 11:42 AM UTC
M
LivaNova raises 2026 currency-adjusted revenue growth outlook
EARNINGS | Nov 04, 2026, 11:42 AM UTC
M
LivaNova Expects 2026 Adjusted EPS of $4.40–$4.50
LivaNova expects 2026 adjusted EPS of $4.40 to $4.50, versus a FactSet estimate of $4.36.
EARNINGS | Nov 04, 2026, 11:27 AM UTC
M
LivaNova Reports Q3 Results, Raises 2026 Revenue and EPS Guidance
LivaNova reported 9.9% revenue growth, or 10.0% on a constant-currency basis, and raised its full-year 2026 revenue and adjusted diluted EPS guidance.
EQUITY | Nov 04, 2026, 11:11 AM UTC
M
LivaNova Q3 Revenue Beats Estimates on Cardiopulmonary Strength
EQUITY | Nov 04, 2026, 11:11 AM UTC
M
LivaNova Q3 GAAP Diluted EPS Falls 78% to $0.11
EARNINGS | Nov 04, 2026, 11:08 AM UTC
M
LivaNova Q3 revenue reaches $393.1 million
LivaNova reported Q3 revenue of $393.1 million versus the IBES estimate of $381.1 million.
EQUITY | Nov 04, 2026, 11:03 AM UTC
L
LivaNova Reports Q3 EPS of USD 0.11
EARNINGS | Nov 04, 2026, 11:02 AM UTC
M
LivaNova reports third-quarter earnings
EQUITY | Nov 04, 2026, 11:02 AM UTC
M
LivaNova Q3 Adjusted EPS $1.23 vs. IBES Estimate $1.06
EARNINGS | Nov 04, 2026, 11:01 AM UTC
L
LivaNova to Announce Third-Quarter 2026 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standar
NEWS | Sep 23, 2026, 01:01 PM UTC
L
LIVN: Growth momentum continues with innovation, reimbursement, and product upgrades fueling future gains
Sustained growth is driven by talent, execution, and innovation, with strong tailwinds from reimbursement and clinical data in epilepsy and supply chain improvements. Margin expansion will be reinvested in new growth are
NEWS | Sep 15, 2026, 04:53 PM UTC
L
LIVN: Growth is fueled by innovation, new product launches, and strong clinical and reimbursement tailwinds
Sustained double-digit growth is driven by talent, execution, and innovation, with new market entries and product launches in epilepsy and cardiopulmonary segments. Margin expansion will fund OSA investments, and strong
NEWS | Sep 15, 2026, 04:27 PM UTC
L
Piper Sandler raises LivaNova price target to $90 from $87
Piper Sandler raised its LivaNova price target to $90.00 per share from $87.00, according to a Benzinga ratings-action item.
EQUITY | Sep 02, 2026, 04:42 PM UTC
L
LivaNova Raises FY2026 Adj EPS Guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 Est; Raises FY2026 Sales Guidance from $1.445B-$1.458B to $
LivaNova (NASDAQ: LIVN ) raises FY2026 Adj EPS guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 analyst estimate. Raises FY2026 sales outlook from $1.445 billion-$1.458 billion to $1.499 billion-$1.513 billion vs $1.507
EARNINGS | Aug 05, 2026, 10:01 AM UTC
L
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Dav
EQUITY | Jul 01, 2026, 11:02 AM UTC
L
Freedom Capital Markets Initiates Coverage On LivaNova with Hold Rating, Announces Price Target of $81
Freedom Capital Markets analyst Keith Hinton initiates coverage on LivaNova (NASDAQ: LIVN ) with a Hold rating and announces Price Target of $81.
EQUITY | Jul 01, 2026, 08:43 AM UTC
M
LIVN: Keybanc Raises Target
Keybanc maintains overweight rating on LivaNova and raises price target to $92
EQUITY | Jun 22, 2026, 01:15 PM UTC